Q-omics provides the consensus-scored DPH6-DT profile across patient tissues and cancer cell-line models. DPH6-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DPH6-DT is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DPH6-DT RNA expression shows 16,672 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where DPH6-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPH6-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPH6-DT survival associations across molecular data types. DPH6-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPH6-DT RNA expression–survival associations across cancer types. High DPH6-DT expression shows unfavorable associations in THCA and CESC, but favorable associations in ACC, KIRC, KIRP and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DPH6-DT RNA expression.
This table summarizes DPH6-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DPH6-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPH6-DT shows lower tumor expression in KIRC, KICH, LUAD, THCA, BRCA and LUSC. The KIRC box plot shows higher DPH6-DT RNA expression in normal versus tumor tissue (log2 FC = −0.899, t-test p < 0.001).
This table shows molecular features associated with DPH6-DT in patient tissues and cancer cell lines. In patient samples, DPH6-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
